Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Boston Therapeutics and Advance Pharma in China Deal for Glucose Product

publication date: Jul 1, 2011
Boston Therapeutics has out-licensed the China rights for an OTC glucose control treatment to Advance Pharmaceutical Company of Hong Kong. Boston Therapeutics claims that Sugardown™, a chewable tablet consisting of complex carbohydrates, slows down carbohydrate digestion and the subsequent rise of blood glucose. To gain China rights to Sugardown, Advance made an equity investment of unspecified size in Boston Therapeutics, which will use the money to support clinical trials of the product. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital